Experience with the third generation cephalosporins, cefoperazone and cefotaxime: report.
The efficacy of the third generation cephalosporins, ceforperazone and cefotaxime, was evaluated in a provincial hospital in a small group of patients with severe infections. In one study, patients with severe sepsis were randomly allocated to a group receiving either cefoperazone or ampicillin (ticarcillin or cloxacillin) and gentamicin. In the other trial, a selected group of ill patients was given cefotaxime. Clinical and laboratory analyses showed that these two drugs are safe, well tolerated and effective in the blind treatment of severe infections.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000667:Ampicillin / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy*; D002438:Cefoperazone / Q000627:therapeutic use*; D002439:Cefotaxime / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003023:Cloxacillin / Q000627:therapeutic use; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D013982:Ticarcillin / Q000627:therapeutic use; D014812:Vitamin K / Q000627:therapeutic use
D005839:Gentamicins; D014812:Vitamin K; D000667:Ampicillin; D002438:Cefoperazone; D013982:Ticarcillin; D002439:Cefotaxime; D003023:Cloxacillin